Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to -$20.0 million.

  • Bioventus' Cash from Financing Activities fell 561850.83% to -$20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$76.5 million, marking a year-over-year decrease of 55208.28%. This contributed to the annual value of -$54.6 million for FY2024, which is 10477.99% down from last year.
  • Bioventus' Cash from Financing Activities amounted to -$20.0 million in Q3 2025, which was down 561850.83% from -$14.7 million recorded in Q2 2025.
  • In the past 5 years, Bioventus' Cash from Financing Activities registered a high of $176.3 million during Q4 2021, and its lowest value of -$62.2 million during Q3 2023.
  • In the last 5 years, Bioventus' Cash from Financing Activities had a median value of -$14000.0 in 2023 and averaged $11.6 million.
  • As far as peak fluctuations go, Bioventus' Cash from Financing Activities skyrocketed by 188485.52% in 2021, and later crashed by 30600714.29% in 2024.
  • Over the past 5 years, Bioventus' Cash from Financing Activities (Quarter) stood at $176.3 million in 2021, then crashed by 103.08% to -$5.4 million in 2022, then surged by 99.74% to -$14000.0 in 2023, then plummeted by 306007.14% to -$42.9 million in 2024, then skyrocketed by 53.38% to -$20.0 million in 2025.
  • Its Cash from Financing Activities stands at -$20.0 million for Q3 2025, versus -$14.7 million for Q2 2025 and $947000.0 for Q1 2025.